GlassScriptPhysician profile
Kaden G Willie
NPI 1790133767
$744.81
in general payments reported to CMS, 2019-2025
21 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.78 · 2021: $61.94 · 2022: $128 · 2023: $90.48 · 2024: $144 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $111.70 | 2025 | |
| Gilead Sciences, INC. | $93.66 | 2025 | |
| Dexcom, INC. | $76.73 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $47.70 | 2022-2023 | Wegovy |
| Lilly USA, LLC | $44.28 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $40.35 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $36.41 | 2022 | |
| Dynavax Technologies Corporation | $35.22 | 2023 | Heplisav-B |
| Viiv Healthcare Company | $30.92 | 2025 | Apretude |
| Hologic Sales and Service, LLC | $28.32 | 2024 | Aptima |
| Boston Scientific Corporation | $27.46 | 2025 | General - Pain Management |
| Abbvie INC. | $24.78 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.43 | 2022 | |
| Astellas Pharma US INC | $17.84 | 2024 | Veozah |
| Insulet Corporation | $16.84 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.07 | 2021 | |
| Pfizer INC. | $16.04 | 2021 | |
| Cranial Technologies, INC | $15.70 | 2024 | Doc Band |
| Tempus Ai, INC | $15.62 | 2024 | |
| Coopersurgical, INC. | $13.68 | 2025 | Paragard T 380a |
| Nevro Corp. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaden Willie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.